AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study published ...

Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...

Shares of Q32 Bio (QTTB) plummeted over 60% in premarket trading Wednesday following mixed results from Phase 2a trials of ...

AnaptysBio discontinues ANB032 for atopic dermatitis after a trial failure, refocusing on autoimmune assets with upcoming ...

H.C. Wainwright downgraded AnaptysBio (ANAB) to Neutral from Buy with a price target of $19, down from $52, after the company announced topline ...

ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...

Atopic dermatitis was associated with a significantly increased bipolar disorder risk among a large population-based cohort in the US.

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms ...

AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a ...